Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance.
about
Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a reviewTreatment of prediabetesAssessment of pancreatic β-cell function: review of methods and clinical applicationsIdentifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetesQuantitative indexes of beta-cell function during graded up&down glucose infusion from C-peptide minimal models.Thiazolidinediones: a new class of antidiabetic drugs.Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial.Interactions between insulin resistance and insulin secretion in the development of glucose intolerance.Enhancing insulin action: from chemical elements to thiazolidinediones.Approaches to preventing mealtime hyperglycaemic excursions.Thiazolidinediones in the treatment of type 2 diabetes.Redefining the clinical management of type 2 diabetes: matching therapy to pathophysiology.Genetically defined pancreatic beta cell failure.Expression and functional activity of PPARgamma in pancreatic beta cells.Thiazolidinediones -- some recent developments.Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats.A Unifying Organ Model of Pancreatic Insulin Secretion.Insulin resistance in patients with polycystic ovary syndrome.Pioglitazone and sulfonylureas: effectively treating type 2 diabetesEarly metabolic markers that anticipate loss of insulin independence in type 1 diabetic islet allograft recipients.Investigational agents that protect pancreatic islet beta-cells from failure.Chronic Angiotensin-(1-7) Improves Insulin Sensitivity in High-Fat Fed Mice Independent of Blood Pressure.Pharmacogenetics of thiazolidinedione therapy.Cholesterol in islet dysfunction and type 2 diabetesThe role of peroxisome proliferator-activated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus.Postprandial hyperglycemia as an etiological factor in vascular failureIn vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion.Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice.Mechanistic Insight and Management of Diabetic Nephropathy: Recent Progress and Future Perspective.Impact of PPARgamma overexpression and activation on pancreatic islet gene expression profile analyzed with oligonucleotide microarrays.Review of methods for measuring β-cell function: Design considerations from the Restoring Insulin Secretion (RISE) Consortium.Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus.Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion.Gestational diabetes mellitus is associated with decreased adipose and placenta peroxisome proliferator-activator receptor γ expression in a Chinese population.Thiazolidinediones improve beta-cell function in type 2 diabetic patients.Pioglitazone attenuates fatty acid-induced oxidative stress and apoptosis in pancreatic beta-cells.Role of PPARG (Pro12Ala) in Malaysian type 2 diabetes mellitus patients
P2860
Q24561401-739BA982-2BE5-4FF4-AB2F-14686799C09BQ26783350-1F243F7C-D8E8-438D-9DA7-E55120DE6EFEQ26829445-EAE236CC-53C1-42AD-9ECB-A597A416B4F1Q28218908-288BEAAA-0BF2-450E-BFDC-5CA5B2CB3AA6Q31711781-6467D165-6A9E-4136-BF23-B22C9E79C0D9Q33607634-9C46AA72-585A-40B4-803B-18C82CAD21DDQ33683750-ABC4CD24-8858-48D8-BB6C-92963EB7D62EQ33993914-2B889C74-28E8-4553-848E-7072C3E2A795Q34268346-D542F693-0FDC-400A-BBC7-3C09C2AA4773Q34549886-20892578-C9D9-4680-B45F-C8A71E677E71Q34628604-7E235E8A-DD62-4740-AF5C-11E640A6C816Q34655587-FA41878D-7482-4609-99DC-9CC695A9350FQ34837085-14B95BE9-721B-45C4-85B0-0E56589EF148Q35047497-2EDB3553-FA1D-46E5-94B0-9E7DAAD52422Q35164761-C2DE6B99-7E49-4BC5-8CF2-333D7D530FD6Q35654399-23AAF474-211B-4291-9077-6C1AA8BE9231Q35837641-5B6920AD-B871-43F4-8C89-87D634343F7BQ35932352-72031858-1290-440C-9C3C-C13C68BA9FFAQ35987456-B31F839F-89C4-4614-A270-0C63D34A8841Q36058109-DA4344C3-EEB2-48E4-BF49-0FBF15AAF65CQ36268360-D2FB12E1-929C-4D98-9CCE-DEC5571E74ECQ36803321-706C5A49-2580-45C4-959C-244436612447Q36918107-ACCB4E46-217E-4F0D-B36D-A413DA298F75Q37075881-DC6AA2F5-9721-49B0-8BF8-DDD9A71C1A33Q37150550-6A09DAE9-C0C0-4687-BB4A-99AC434B7BDDQ37464262-AE4398A9-40DB-4D13-8D3D-B33C5FDB7094Q37577126-E2FFD166-4907-49B7-BA5C-D17749C410F3Q37662933-24A278D7-4058-48E2-8BA4-1E5DE35D39B4Q37721470-049E04B7-5FD2-41C0-B3F1-D440157CA68DQ38341682-722D4A7C-9513-495C-B9A3-1EB3E3C89F4BQ39298394-56A89DA5-7FD3-4C6E-959D-475899BE931EQ43902805-669873B5-7FED-4148-89CF-8961EBF035FAQ44660894-C5A8701A-71FD-49C3-9D92-1A9413AFC2F1Q49194295-2255FC1A-11D6-4B09-8A86-E8B0A947D5A1Q51485541-568FC9C2-A7A5-40C6-9AF0-6D55C0901A72Q53544467-80E0C561-13B9-4A6D-A6D4-CA48FD4B143CQ57278795-D303A759-6667-424D-8E46-8562190DA76D
P2860
Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 1997
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment with the oral antidi ...... th impaired glucose tolerance.
@en
Treatment with the oral antidi ...... th impaired glucose tolerance.
@nl
type
label
Treatment with the oral antidi ...... th impaired glucose tolerance.
@en
Treatment with the oral antidi ...... th impaired glucose tolerance.
@nl
prefLabel
Treatment with the oral antidi ...... th impaired glucose tolerance.
@en
Treatment with the oral antidi ...... th impaired glucose tolerance.
@nl
P2093
P2860
P356
P1476
Treatment with the oral antidi ...... th impaired glucose tolerance.
@en
P2093
D A Ehrmann
K S Polonsky
M K Cavaghan
P2860
P304
P356
10.1172/JCI119562
P407
P577
1997-08-01T00:00:00Z